<span item_type="fundamental" item_id="cb98dc69a8ca7c1d3e9023e89a344913" counter_id="ST/US/RLYB" env="prod"></span><span item_type="announcement" item_id="579778568094418561" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 212 K, beating the estimate of USD 66.67 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.36, beating the estimate of USD -0.2133.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -7.387 M.</p><p></p><h3>Revenue</h3><ul><li>Revenue for the third quarter of 2025 was $0.2 million, compared to $0.3 million for the same period in 2024, primarily due to changes in the collaboration agreement with Johnson &amp; Johnson.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm"></span></li></ul><h3>Research &amp; Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses were $4.1 million for the third quarter of 2025, a decrease from $8.2 million in the same period in 2024. This decrease was mainly due to reduced development costs for RLYB212 and other program candidates, as well as decreased payroll expenses following a workforce reduction.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm"></span></li></ul><h3>General &amp; Administrative (G&amp;A) Expenses</h3><ul><li>G&amp;A expenses were $3.0 million for the third quarter of 2025, down from $4.1 million in the same period in 2024, primarily due to lower payroll expenses resulting from a reduced headcount.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm"></span></li></ul><h3>Net Income</h3><ul><li>Rallybio reported a net income of $16.0 million, or $0.36 per common share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $0.26 per common share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm"></span></li></ul><h3>Cash Position</h3><ul><li>As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $59.3 million. The company expects these resources to support operations through 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Rallybio anticipates reporting data from the RLYB116 Phase 1 confirmatory PK/PD study in the fourth quarter of 2025. The company is confident in RLYB116’s potential as an effective therapeutic for complement-mediated diseases and plans to advance its development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm"></span></li></ul>

Rallybio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 212 K